Company: CERO
Filing Date: 2025-11-28
Form Type: DEF 14A
Source: 0001213900-25-115783
Chunk: 30

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-28
Form: DEF 14A
Chunk 30
---
 will be effective upon its filing or at such later time as specified in the Certificate of Amendment. If the stockholders do not approve this Proposal No. 1, the Certificate of Amendment will not be filed with the Secretary of State of the State of Delaware. Dissenters’ Rights No dissenters’ rights are available under the General Corporation Law of the State of Delaware (the “DGCL”) or under the Certificate of Incorporation or the Second Amended and Restated Bylaws of the Company (the “Bylaws”) to any stockholder who dissents from this Proposal No. 1. Interests of Directors and Executive Officers Our directors and executive officers do not have substantial interest, directly or indirectly, in the matters set forth in this proposal except to the extent of their ownership of shares of Common Stock or any other of our securities. 15

Vote Required; Board Recommendation The affirmative vote of the holders of a majority of the votes properly cast will be required to approve this proposal. Abstentions will have no effect on the outcome of this proposal and we do not expect any broker non -voteswith respect to such proposal. Section 242(d)(2) of the DGCL provides that a reverse stock split of a class of securities listed on a national securities exchange may be approved by the vote of a majority of the votes cast. The shares of our common stock are currently suspended from trading on Nasdaq, with the delisting thereof stayed pending the resolution of our appeal. However, if our common stock is not listed on Nasdaq as of the effective date of the amendment to effectuate the reverse stock split, then such amendment will require the vote of a majority of the outstanding shares of our common stock.

| THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE APPROVAL OF AN AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO COMBINE OUTSTANDING SHARES OF OUR COMMON STOCK INTO A LESSER NUMBER OF OUTSTANDING SHARES, BY A RATIO OF NOT LESS THAN ONE-FOR-40 AND NOT MORE THAN ONE-FOR-150, WITH THE EXACT RATIO TO BE SET WITHIN THIS RANGE BY OUR BOARD IN ITS SOLE DISCRETION. |     | ✓ |

16 PROPOSAL NO. 2: NASDAQ STOCK ISSUANCE (SERIES E) PROPOSAL Overview As described in more detail below, in October 2025, the Company issued an aggregate of 3,816 shares of Series E Preferred Stock in the October